中晚期卵巢癌術(shù)后化療臨床觀察

1、中晚期卵巢癌術(shù)后化療臨床觀察【摘要】目的分析兩種給藥途徑(順鉗+紫杉 醇靜脈化療，順鉗+紫杉醇腹腔化療)對(duì)中晚期卵巢癌 術(shù)后的化療效果。方法選擇2011年6月至2012年6月 本院收治的確診為卵巢癌中晚期并已行腫瘤細(xì)胞減滅術(shù)后 的48例患者，隨機(jī)分為腹腔化療組，靜脈化療組，各 24例，觀察兩組不良反應(yīng)，近期療效，化療完成情況 等。結(jié)果腹腔化療組和靜脈化療組的有效率分別為83. 3% (20/24 )和79. 1% ( 19/24 ), 差異無統(tǒng)計(jì)學(xué)意義 (p>0. 05), 毒副反應(yīng)的發(fā)生率腹腔化療組為95. 8% (23/24),靜脈化療組100% (24/24),差異無統(tǒng)計(jì)學(xué)意 義(

2、p>0. 05)o但重度消化道副作用腹腔化療組33. 3% (8/24),靜脈化療組0% (0/24),差異有統(tǒng)計(jì)學(xué)意義 (p0. 05),見表 2。2. 2毒副反應(yīng)腹腔化療組及靜脈化療組患者毒副反應(yīng) 主要為骨髓抑制，表現(xiàn)為白細(xì)胞明顯下降，對(duì)血小板及 血紅蛋白影響較小。注射局部靜脈炎，脫發(fā)，消化道反 應(yīng)及周圍神經(jīng)毒性兩組發(fā)生率近似(見表3),均未出現(xiàn)心 肝、腎功能損害、腸梗阻及發(fā)熱，過敏反應(yīng)，但靜脈給 藥組中重度消化道反應(yīng)(ii度及iii度)8例(33. 3%),腹 腔化療組2例(8.3%),兩組間比較差異有統(tǒng)計(jì)學(xué)意義(p7 bamias a, bamia c, zagouri f, e

3、t al. improved survival trends in pla.tinum-resistant patients with advanced ovarian , fallopian or peritoneal cancer treated with first-line pad itaxel/ platinum chemotherapy： the impact of novel agents. oncology, 2013,84 (3)： 158-65._8 lee se, bairstow sf, werling jo, et al. paclitaxel nanosuspens

4、ions fortargetedchemotherapy-nanosuspensionpreparation,characterization, and use pharm dev technol,2013apr 25.9 曹澤毅婦科常見腫瘤診治指南.3版.北京：人民 衛(wèi)生出版社,2010： 7293.10 jordan s, steer c, defazio a, et al patternsof chemotherapy treatment for women with invasive epithelial ovarian cancer -a populationbased study.

5、 gynecol oncol,2013,129 (2)： 310-7.11 landrum lm, java j, mathews ca, et al. prognostic factors for stage iii epithelial ovarian cancer treated with intraperitoneal chemotherapy： a gynecologic oncology group study. gynecol oncol, 2013： s0090-8258 (13) 00214-x.2 mendivil aa, micha jp, brown jv, et al

6、.increased incidence of severe gastrointestinal events with first-line pad itaxel , carboplatin , and vorinostat chemotherapy for advanced-stage epithelial ovarian , primary peritoneal , and fallopian tube cancer. int j gynecol cancer, 2013, 23 (3)： 533-913 chang cl, hsu yt, wu cc, et al. dose-dense chemotherapy improves mechanisms of antitumor immune response cancer res, 2013, 73 (1 )： 119-2714 nccn clinical practice guidelines in oncology : ovarian cancer. v.2.2011, 0v-3 eb/ol. http： /www. nccn. org, 2011-10-20.15 glaze s, teitelbaum l, chu p, et al.dose-dense pad itaxel with carbopl